2025-06-10-Jefferies-英斯美德公司（INSM）_Ph2B结果表明TPIP将成为肺动脉高压的基石疗法_13页_1mb

Company Overview: Insmed Inc (INSM) is a global biopharmaceutical company focused on developing therapies for pulmonary diseases and genetic disorders, including Brensocatib, TPIP, and ARIKAYCE.

Key Findings: Jefferies sets a new $121 price target for INSM, a 71% upside from the current $70.68 price. Positive Phase 2b data for TPIP in pulmonary arterial hypertension (PAH) showed statistically significant primary endpoints: a 35% placebo-adjusted PVR reduction and a 35.5m increase in 6MWD, outperforming expectations and competitor drugs. TPIP is expected to advance to Phase 3 in early 2026.

Financial Projections: Revenue models project $2.6B peak sales for TPIP in PAH (60% probability of success) and PH-ILD (50% PoS). Bre NSA holds broad potential in bronchiectasis with peak sales of $5.4B in that indication (85% PoS). Valuation is DCF-based with a WACC of 11%.

Investment Thesis: High-growth opportunities driven by TPIP's strong data, once-daily dosing, and Tolerability profiles, positioning it to disrupt the PAH market and potentially shift treatment paradigms. Brensocatib and ARIKAYCE offer sequential revenue opportunities.

Risks: Clinical, regulatory, commercial, and competitive risks, including trial uncertainties and pricing pressures. Upside scenario includes successful Phase 3 data and broad market adoption.